Literature DB >> 28986623

[Health-related quality of life after implantation of a keratoprosthesis with biological haptic].

A Frings1, S Schrader2, K Hille3, I Staab2, G Geerling2.   

Abstract

BACKGROUND: Many studies report comparatively good long-term results among patients with keratoprostheses with biological haptic. However, overall costs are correspondingly high. A clear cost-benefit relationship is therefore desirable.
OBJECTIVE: This study investigates health-related quality of life after implantation of a keratoprosthesis with biological haptic.
MATERIALS AND METHODS: We present a retrospective analysis of medical data of 25 patients treated between 1996 and 2006 at the Department of Ophthalmology, University Hospital Homburg/Saar and the Klinikum Offenburg. Health-related quality of life was assessed by means of a questionnaire based on validated instruments, with particular emphasis on physical symptoms, mental health, functional limitations, and social interactions.
RESULTS: At a patient age of 49.8 ± 15.7 years (minimum-maximum: 19-78 years; 6 female, 19 male), the mean duration of corneal blindness was 13.8 ± 13.1 years (minimum-maximum: 1-47 years). Changes in visual acuity and subjective satisfaction were statistically significant (p <0.001). Quality of life (on a scale of 1 to 6: median 2) at the time "before the onset of eye disease" and ≥15 months after surgery were identical. Patients with a postoperative visual acuity ≤0.1 (n =11) also showed a statistically significant (p =0.016) benefit in this context.
CONCLUSION: The expenditures and costs of keratoprosthetics can be justified by an improvement in the health-related quality of life of the persons concerned. Even a postoperative visual acuity of ≤0.1 correlates with a statistically significant improvement in the subjective quality of life of these patients.

Entities:  

Keywords:  Blindness; Cornea; Cost–benefit analysis; Odontokeratoprosthesis; Patient satisfaction

Mesh:

Year:  2018        PMID: 28986623     DOI: 10.1007/s00347-017-0576-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  22 in total

1.  Interpreting SF-36 summary health measures: a response.

Authors:  J E Ware; M Kosinski
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

2.  Sight and comfort: complex procedures in end-stage Stevens-Johnson syndrome.

Authors:  G Geerling; C S C Liu; J K G Dart; P Sieg; J Herold; J R O Collin
Journal:  Eye (Lond)       Date:  2003-01       Impact factor: 3.775

3.  Association between vision loss and higher medical care costs in Medicare beneficiaries costs are greater for those with progressive vision loss.

Authors:  Jonathan C Javitt; Zhiyuan Zhou; Richard J Willke
Journal:  Ophthalmology       Date:  2007-02       Impact factor: 12.079

4.  [Osteo-odonto-keratoprosthesis in a case treated for anchylobepharon and total simbleraphon].

Authors:  B Strampelli; A Valvo; E Tusa
Journal:  Ann Ottalmol Clin Ocul       Date:  1965-06

5.  [Long-term outcome of keratoprosthesis with biological support].

Authors:  K Hille
Journal:  Ophthalmologe       Date:  2018-01       Impact factor: 1.059

Review 6.  [Keratoprosthesis with Biological Haptic - The Düsseldorf-Offenburg-Experience with Osteo-Odonto- and Tibia-Keratoprosthesis].

Authors:  Gerd Geerling; Konrad Hille
Journal:  Klin Monbl Augenheilkd       Date:  2017-06-06       Impact factor: 0.700

7.  The economic burden of major adult visual disorders in the United States.

Authors:  David B Rein; Ping Zhang; Kathleen E Wirth; Paul P Lee; Thomas J Hoerger; Nancy McCall; Ronald Klein; James M Tielsch; Sandeep Vijan; Jinan Saaddine
Journal:  Arch Ophthalmol       Date:  2006-12

8.  Standards for modified osteoodontokeratoprosthesis (OOKP) surgery according to Strampelli and Falcinelli: the Rome-Vienna Protocol.

Authors:  Konrad Hille; Günther Grabner; Christopher Liu; Paolo Colliardo; Giovanni Falcinelli; Maurizio Taloni; GianCarlo Falcinelli
Journal:  Cornea       Date:  2005-11       Impact factor: 2.651

Review 9.  [Clinical management of severe ocular surface disease].

Authors:  J Stoiber; G Grabner
Journal:  Klin Monbl Augenheilkd       Date:  2005-07       Impact factor: 0.700

10.  Impact of vision loss on costs and outcomes in medicare beneficiaries with glaucoma.

Authors:  Thomas Bramley; Patti Peeples; John G Walt; Marta Juhasz; Jan E Hansen
Journal:  Arch Ophthalmol       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.